ProQR Therapeutics downgraded by Stifel with a new price target
$PRQR
Biotechnology: Pharmaceutical Preparations
Health Care
Stifel downgraded ProQR Therapeutics from Buy to Hold and set a new price target of $3.00 from $20.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/29/2024 | $6.00 → $14.00 | Outperform → Strong Buy | Raymond James |
| 11/8/2023 | $2.00 | Neutral → Buy | Chardan Capital Markets |
| 3/30/2023 | $1.50 → $5.00 | Mkt Perform → Mkt Outperform | JMP Securities |
| 12/22/2022 | $0.80 → $5.00 | Neutral → Overweight | Cantor Fitzgerald |
| 2/14/2022 | $18.00 → $8.00 | Buy | Chardan Capital |
| 2/14/2022 | $37.00 → $1.70 | Buy → Neutral | Citigroup |
| 2/14/2022 | $29.00 → $8.00 | Market Outperform | JMP Securities |
| 2/14/2022 | $20.00 → $4.00 | Buy | HC Wainwright & Co. |
6-K - ProQR Therapeutics N.V. (0001612940) (Filer)
6-K - ProQR Therapeutics N.V. (0001612940) (Filer)
424B5 - ProQR Therapeutics N.V. (0001612940) (Filer)
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (the "Company"), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that John Maraganore, PhD, biopharma industry leader and the former founding CEO of Alnylam Pharmaceuticals, has joined ProQR as a strategic advisor. "It is a great honor to have John engaged with ProQR as a strategic advisor to the Supervisory Board to support us in defining the next steps for the Company, while we continue to analyze data from the Illuminate trial of sepofarsen and identify next steps for the program, if any,"
Top-line data from pivotal Phase 2/3 Illuminate trial of sepofarsen for CEP290-mediated LCA10 anticipated late Q1/early Q2 2022Five-target collaboration with Lilly highlights significant potential of ProQR's Axiomer® RNA base-editing platform and strengthens financial position with $50 million in upfront and equity and up to $1.25 billion in milestonesQR-421a Phase 2/3 Sirius and Celeste trials in Usher syndrome and retinitis pigmentosa on track to start by year end 2021Company to host an "Analyst Event" on November 18, 2021 to highlight clinical stage pipeline programs and Axiomer® RNA editing platform LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- ProQR The
Senior leader with extensive global rare disease commercialization experienceTop-line data from Phase 2/3 pivotal Illuminate trial of sepofarsen for CEP290-mediated LCA10 on track for H1 2022 LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced the appointment of Theresa Heggie as Chief Commercial Officer reporting to Daniel de Boer, Founder and CEO. In this newly created leadership position, Ms. Heggie will be responsible for overseeing the Company's commercial strategy and global comme
ProQR scientists report for the first time in the ADAR RNA editing field in vivo proof of target engagement (RNA editing) leading to meaningful changes in biomarkers in NHPs using Axiomer™ RNA Editing OligonucleotidesPreclinical proof of concept for the Company's AX-0810 program targeting NTCP for cholestatic diseases presented at ASGCT Annual MeetingManagement webinar May 9, 2024 at 8:00 am EDT LEIDEN, Netherlands & CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced new preclinical data for its proprietary Axiomer™ RNA editing technology platform, incl
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 22, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced that ProQR management will host an investor conference call and webcast to discuss the Company's Axiomer RNA editing technology platform following the recently announced partnership expansion with Lilly. ProQR will host the call on December 22, 2022, at 8:15am EST. The live and archived webcast of the presentation will be accessible through this webcast link, or to access the live call by phone please register here. A dial-in and unique PIN will be provided to join the call. The
In line with corporate strategy update in April, ProQR to focus exclusively on the development of the Axiomer® RNA editing technology platform across multiple therapeutic areas; update on initial pipeline targets expected in late 2022/early 2023Additional pivotal trial recommended by EMA for sepofarsen prior to a regulatory submissionCompany will seek a strategic partner for ophthalmology assets Workforce reduction to be implemented within clinical stage ophthalmology programs Cash runway extended into 2026 Conference call today at 8:15am EDT LEIDEN, Netherlands & CAMBRIDGE, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (the "Company"), a company dedica
SC 13G/A - ProQR Therapeutics N.V. (0001612940) (Subject)
SC 13G/A - ProQR Therapeutics N.V. (0001612940) (Subject)
SC 13G - ProQR Therapeutics N.V. (0001612940) (Subject)
Raymond James upgraded ProQR Therapeutics from Outperform to Strong Buy and set a new price target of $14.00 from $6.00 previously
Chardan Capital Markets upgraded ProQR Therapeutics from Neutral to Buy and set a new price target of $2.00
JMP Securities upgraded ProQR Therapeutics from Mkt Perform to Mkt Outperform and set a new price target of $5.00 from $1.50 previously
AX-0810 targeting NTCP for cholestatic diseases to be first ProQR Axiomer™ RNA editing program to enter the clinic Company to host virtual Investor and Analyst Event in December to highlight translational data and clinical plans for AX-0810, as well as AX-1412, targeting B4GALT1 for cardiovascular diseases, and progress made across the Axiomer platform€89.4 million cash and cash equivalents as of end of Q3, plus $82.1 million gross proceeds from October financing providing runway into mid-2027 LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies
LEIDEN, the Netherlands and CAMBRIDGE, Mass., Oct. 25, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) ("ProQR"), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the closing of its previously announced underwritten public offering of 18,000,000 ordinary shares (the "Offering") at a public offering price of $3.50 per share, for total gross proceeds of $63.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by ProQR. All of the shares in the Offering were sold by ProQR. In addition, ProQR today announced the closing o
LEIDEN, Netherlands and CAMBRIDGE, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) ("ProQR"), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the pricing of its previously announced underwritten public offering of 18,000,000 ordinary shares (the "Offering") at a public offering price of $3.50 per share, for total gross proceeds of $63.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by ProQR. All of the shares are being offered by ProQR. In addition, ProQR has granted the underwriters a 30-day opti
ProQR Therapeutics NV (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it will participate in the RNA Editing Summit, June 18-20, 2024, in Boston, Massachusetts. As part of the conference program, Gerard Platenburg, Chief Scientific Officer and Co-Founder, ProQR Therapeutics, will present on June 20, 2024 at 2:00pm ET:
Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and maintains $2.5 price target.
HC Wainwright & Co. analyst Andrew Fein reiterates ProQR Therapeutics (NASDAQ:PRQR) with a Buy and maintains $5 price target.